BCAL Appoints Anne-Louise Arnett as Chief Executive Officer
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Ms. Arnett brings extensive experience in medical technology and has a successful track record in launching diagnostic products in various markets. Shane Ryan will transition to Director Clinical Affairs Breast Cancer to ensure continuity during this leadership change. Jayne Shaw will move from Executive Chair to Non-Executive Chair, reflecting the company's evolving governance structure.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- BCAL Accelerates Rollout of Avantect Early Detection Tests
- Half Yearly Report and Accounts
- Shareholder Update
- Quarterly Activities/Appendix 4C Cash Flow Report
- BCAL Early Cancer Detection Tests Update
Later from BCAL Diagnostics
- BCAL Launches Early Detection Cancer Platform
- BCAL Develops New Blood Test for Breast Cancer Recurrence
- BCAL Secures Funding for FY2027
- BCAL to Acquire Shares in Genetic Signatures
- Bioshares Conference Investor Presentation
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics